These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 15660442)
21. Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy. Bai X; Liu J; Li L; Faries D Pharm Stat; 2015; 14(6):448-54. PubMed ID: 26436533 [TBL] [Abstract][Full Text] [Related]
22. The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Westreich D; Cole SR; Young JG; Palella F; Tien PC; Kingsley L; Gange SJ; Hernán MA Stat Med; 2012 Aug; 31(18):2000-9. PubMed ID: 22495733 [TBL] [Abstract][Full Text] [Related]
23. Simulating from marginal structural models with time-dependent confounding. Havercroft WG; Didelez V Stat Med; 2012 Dec; 31(30):4190-206. PubMed ID: 22826156 [TBL] [Abstract][Full Text] [Related]
24. Comparison of dynamic treatment regimes via inverse probability weighting. Hernán MA; Lanoy E; Costagliola D; Robins JM Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):237-42. PubMed ID: 16611197 [TBL] [Abstract][Full Text] [Related]
25. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987 [TBL] [Abstract][Full Text] [Related]
26. Mortality and its predictors among highly active antiretroviral therapy naive hiv-infected individuals: data from prospective cohort study in Ukraine. Zhyvytsia D Georgian Med News; 2014; (232-233):69-74. PubMed ID: 25214276 [TBL] [Abstract][Full Text] [Related]
27. Semiparametric estimation of structural failure time models in continuous-time processes. Yang S; Pieper K; Cools F Biometrika; 2020 Mar; 107(1):123-136. PubMed ID: 33162561 [TBL] [Abstract][Full Text] [Related]
28. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT; AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144 [TBL] [Abstract][Full Text] [Related]
29. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852 [TBL] [Abstract][Full Text] [Related]
30. Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies. Hogan JW; Lancaster T Stat Methods Med Res; 2004 Feb; 13(1):17-48. PubMed ID: 14746439 [TBL] [Abstract][Full Text] [Related]
31. History-adjusted marginal structural models for estimating time-varying effect modification. Petersen ML; Deeks SG; Martin JN; van der Laan MJ Am J Epidemiol; 2007 Nov; 166(9):985-93. PubMed ID: 17875580 [TBL] [Abstract][Full Text] [Related]
32. Effect modification by time-varying covariates. Robins JM; Hernán MA; Rotnitzky A Am J Epidemiol; 2007 Nov; 166(9):994-1002; discussion 1003-4. PubMed ID: 17875581 [TBL] [Abstract][Full Text] [Related]
33. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]. Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G; Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363 [TBL] [Abstract][Full Text] [Related]
34. Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study. Maruza M; Albuquerque MF; Braga MC; Barbosa MT; Byington R; Coimbra I; Moura LV; Batista JD; Diniz GT; Miranda-Filho DB; Lacerda HR; Rodrigues LC; Ximenes RA Int J Tuberc Lung Dis; 2012 May; 16(5):618-24. PubMed ID: 22410415 [TBL] [Abstract][Full Text] [Related]
35. Constructing inverse probability weights for marginal structural models. Cole SR; Hernán MA Am J Epidemiol; 2008 Sep; 168(6):656-64. PubMed ID: 18682488 [TBL] [Abstract][Full Text] [Related]
36. Marginal structural models and causal inference in epidemiology. Robins JM; Hernán MA; Brumback B Epidemiology; 2000 Sep; 11(5):550-60. PubMed ID: 10955408 [TBL] [Abstract][Full Text] [Related]
37. Time scale and adjusted survival curves for marginal structural cox models. Westreich D; Cole SR; Tien PC; Chmiel JS; Kingsley L; Funk MJ; Anastos K; Jacobson LP Am J Epidemiol; 2010 Mar; 171(6):691-700. PubMed ID: 20139124 [TBL] [Abstract][Full Text] [Related]
38. Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. Lusivika-Nzinga C; Selinger-Leneman H; Grabar S; Costagliola D; Carrat F BMC Med Res Methodol; 2017 Dec; 17(1):160. PubMed ID: 29202691 [TBL] [Abstract][Full Text] [Related]
39. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516 [TBL] [Abstract][Full Text] [Related]
40. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]